Koers Acasti Pharma Inc. Toronto S.E.
Aandelen
ACST
CA00430K8730
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 36,86 mln. 26,86 mln. 25,06 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -18 mln. -13,11 mln. -12,24 mln. | Nettowinst (verlies) 2025 * | -23 mln. -16,76 mln. -15,64 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,03
x | K/w-verhouding 2025 * |
-2,61
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 83,98% |
Recentste transcriptie over Acasti Pharma Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Prashant Kohli
CEO | Chief Executive Officer | 52 | 01-08-21 |
Director of Finance/CFO | 52 | 05/01 | |
Carrie D'Andrea
CTO | Chief Tech/Sci/R&D Officer | 52 | 08-05-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
A. Davis
BRD | Director/Board Member | 57 | 10-10-23 |
Director/Board Member | - | 10-10-23 | |
Santosh Kottayil
BRD | Director/Board Member | - | 10-10-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,25% | 699 mld. | |
+28,59% | 571 mld. | |
-3,55% | 364 mld. | |
+18,16% | 326 mld. | |
+4,36% | 286 mld. | |
+14,81% | 236 mld. | |
+4,93% | 198 mld. | |
-9,78% | 194 mld. | |
-3,69% | 149 mld. |